AVTX · Categories · Form 4

AVTX - SEC Form 4 insider transactions

Avalo Therapeutics Inc. (AVTX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for AVTX

• 10h
  SEC Form 4 filed by Director Lind Kevin Robert

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 10h
  SEC Form 4 filed by Director Truex Samantha

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 10h
  SEC Form 4 filed by Director Kaplan Gilla

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 10h
  SEC Form 4 filed by Director Kantoff Aaron

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 10h
  SEC Form 4 filed by Director Jain Rita

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 10h
  SEC Form 4 filed by Director Heffernan Michael Thomas

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 3d
  Chief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $10,864 worth of shares (679 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 9d
  Chief Executive Officer Neil Garry Arthur was granted 100,200 shares, increasing direct ownership by 111% to 190,314 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 9d
  Chief Legal Officer Varki Paul was granted 24,300 shares, increasing direct ownership by 669% to 27,934 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 9d
  Chief Medical Officer Doyle Mittie was granted 43,500 shares, increasing direct ownership by 1,201% to 47,122 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 9d
  Chief Financial Officer Sullivan Christopher Ryan was granted 39,900 shares, increasing direct ownership by 9,433% to 40,323 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 9d
  Chief Strategy Officer Riley Jennifer was granted 34,200 shares, increasing direct ownership by 1,288% to 36,855 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 16d
  Chief Medical Officer Doyle Mittie sold $56,280 worth of shares (3,000 units at $18.76) as part of a pre-agreed trading plan and exercised 3,000 shares at a strike of $12.65 (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 24d
  Chief Financial Officer Sullivan Christopher Ryan sold $448,818 worth of shares (18,606 units at $24.12) as part of a pre-agreed trading plan and exercised 18,606 shares at a strike of $9.88 (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 28d
  Chief Legal Officer Varki Paul exercised 75,063 shares at a strike of $12.53 and sold $1,513,673 worth of shares (75,063 units at $20.17) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 28d
  Chief Medical Officer Doyle Mittie exercised 108,234 shares at a strike of $11.40 and sold $2,230,367 worth of shares (108,234 units at $20.61) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 28d
  Chief Financial Officer Sullivan Christopher Ryan exercised 47,000 shares at a strike of $8.04 and sold $948,722 worth of shares (47,000 units at $20.19) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 28d
  Director Chan Mitchell sold $72,461 worth of shares (3,167 units at $22.88) as part of a pre-agreed trading plan, decreasing direct ownership by 50% to 3,166 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 34d
  Chief Financial Officer Sullivan Christopher Ryan sold $222,589 worth of shares (16,915 units at $13.16) as part of a pre-agreed trading plan, decreasing direct ownership by 98% to 423 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 57d
  SEC Form 4 filed by Doyle Mittie

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 62d
  SEC Form 4 filed by Sullivan Christopher Ryan

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 62d
  SEC Form 4 filed by Doyle Mittie

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 64d
  SEC Form 4 filed by Jain Rita

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 64d
  SEC Form 4 filed by Lind Kevin Robert

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 65d
  SEC Form 4 filed by Truex Samantha

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 65d
  SEC Form 4 filed by Kantoff Aaron

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 65d
  SEC Form 4 filed by Kaplan Gilla

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 65d
  SEC Form 4 filed by Neil Garry Arthur

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 65d
  SEC Form 4 filed by Sullivan Christopher Ryan

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 65d
  SEC Form 4 filed by Chan Mitchell

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 65d
  SEC Form 4 filed by Goldman Jonathan

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 78d
  SEC Form 4 filed by Doyle Mittie

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 94d
  SEC Form 4 filed by Chief Legal Officer Varki Paul

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 94d
  SEC Form 4 filed by Chief Strategy Officer Riley Jennifer

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 94d
  SEC Form 4 filed by Chief Medical Officer Doyle Mittie

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 94d
  SEC Form 4 filed by Chief Business Officer Boyd Taylor

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 94d
  SEC Form 4 filed by Chief Financial Officer Sullivan Christopher Ryan

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 94d
  SEC Form 4 filed by Chief Executive Officer Neil Garry Arthur

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 150d
  SEC Form 4 filed by Director Lind Kevin Robert

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 150d
  SEC Form 4 filed by Director Jain Rita

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 174d
  Chief Medical Officer Doyle Mittie covered exercise/tax liability with 1,013 shares, decreasing direct ownership by 22% to 3,622 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 174d
  Chief Strategy Officer Riley Jennifer covered exercise/tax liability with 637 shares, decreasing direct ownership by 19% to 2,655 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 174d
  Chief Legal Officer Varki Paul covered exercise/tax liability with 1,016 shares, decreasing direct ownership by 22% to 3,634 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 174d
  Chief Financial Officer Sullivan Christopher Ryan covered exercise/tax liability with 155 shares, decreasing direct ownership by 0.89% to 17,338 units (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 199d
  Director Goldman Jonathan sold $162,937 worth of shares (11,367 units at $14.33) and exercised 8,200 shares at a strike of $9.88, closing all direct ownership in the company (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 241d
  SEC Form 4 filed by Chief Business Officer Boyd Taylor

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 245d
  SEC Form 4 filed by Director Lind Kevin Robert

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 245d
  SEC Form 4 filed by Director Jain Rita

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 351d
  SEC Form 4 filed by Director Truex Samantha

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 351d
  SEC Form 4 filed by Director Chan Mitchell

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 351d
  SEC Form 4 filed by Director Goldman Jonathan

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 351d
  SEC Form 4 filed by Director Kaplan Gilla

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 351d
  SEC Form 4 filed by Director Kantoff Aaron

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 351d
  SEC Form 4 filed by Director Heffernan Michael Thomas

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 351d
  SEC Form 4 filed by Director Almenoff June Sherie

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 351d
  SEC Form 4 filed by Director Jain Rita

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 429d
  Director Chan Mitchell converted options into 3,167 shares (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 429d
  Director Goldman Jonathan converted options into 3,167 shares (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 429d
  Director Truex Samantha converted options into 3,167 shares (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
• 429d
  Director Kantoff Aaron converted options into 3,167 shares (SEC Form 4)

  4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

Other AVTX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends